An iPSC model of fragile X syndrome reflects clinical phenotypes and reveals m6A-mediated epi-transcriptomic dysregulation underlying synaptic dysfunction
Ziyuan Guo,Lu Lu,Avijite Kumer Sarkar,Lan Dao,Yanchen Liu,Chunlong Ma,Phyo Han Thwin,Xuyao Chang,George Yoshida,Annie Li,Cenjing Wang,Grace Westerkamp,Lauren Schmitt,Maag Chelsey,Monzon Stephanie,Yu Zhao,Yaping Liu,Xiong Wang,Ling-Qiang Zhu,Dan Liu,Jason Tchieu,Makoto Miyakoshi,Haining Zhu,Christina Gross,Ernest Pedapati,Nathan Salomonis,Craig Erickson
DOI: https://doi.org/10.1101/2024.10.14.618205
2024-10-19
Abstract:Fragile X syndrome (FXS), the leading genetic cause of intellectual disability, arises from FMR1 gene silencing and loss of the FMRP protein. FMRP is known to bind to and regulate the stability of m6A-containing transcripts. However, how loss of FMRP impacts on transcriptome-wide m6A modifications in FXS patients remains unknown. To answer this question, we generated cortical neurons differentiated from induced pluripotent stem cells (iPSC) derived from healthy subjects and FXS patients. In electrophysiology recordings, we validated that synaptic and neuronal network defects in iPSC-derived FXS neurons corresponded to the clinical EEG data of the patients from which the corresponding iPSC line was derived. In analysis of transcriptome-wide methylation, we show that FMRP deficiency led to increased translation of m6A writers, resulting in hypermethylation that primarily affecting synapse-associated transcripts and increased mRNA decay. Conversely, in the presence of an m6A writer inhibitor, synaptic defects in FXS neurons were rescued. Taken together, our findings uncover that an FMRP-dependent epi-transcriptomic mechanism contributes to FXS pathogenesis by disrupting m6A modifications in FXS, suggesting a promising avenue for m6A-targeted therapies.
Neuroscience